CTSD and posterior cortical atrophy: We have previously shown in one of the most challenging subsets of subjects presenting with a tPSA of 2‐10 ng/mL, prostate volume ≥35 mL, no prior history of PCa and a normal DRE, that the combined measurement of two novel glycoproteins thrombospondin‐1 (THBS1) and cathepsin D (CTSD) can improve the identification of clinically significant PCa.15 Based on these results we have developed a new test named Proclarix.